.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
US Army
Colorcon
Fuji
Cipla
Moodys
Boehringer Ingelheim
AstraZeneca
Mallinckrodt

Generated: January 19, 2018

DrugPatentWatch Database Preview

Patents Expiring in April 2021

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-002Jul 23, 2014RXYesYes➤ Subscribe➤ SubscribeYY
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-002Jul 23, 2014RXYesYes➤ Subscribe➤ SubscribeYY
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-001Jul 23, 2014RXYesNo➤ Subscribe➤ SubscribeYA METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-001Jul 23, 2014RXYesNo➤ Subscribe➤ SubscribeYA METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-001Jul 23, 2014RXYesNo➤ Subscribe➤ SubscribeYYFOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-001Jul 23, 2014RXYesNo➤ Subscribe➤ SubscribeYY
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-001Jul 23, 2014RXYesNo➤ Subscribe➤ SubscribeYY
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-002Jul 23, 2014RXYesYes➤ Subscribe➤ SubscribeYA METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-002Jul 23, 2014RXYesYes➤ Subscribe➤ SubscribeYA METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
Gilead Sciences IncZYDELIGidelalisibTABLET;ORAL205858-002Jul 23, 2014RXYesYes➤ Subscribe➤ SubscribeYYFOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Harvard Business School
Fuji
Farmers Insurance
Johnson and Johnson
Express Scripts
UBS
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot